Emergent Biosolutions Inc (NYSE:EBS) has a beta value of 2.09 and has seen 1.37 million shares traded in the last trading session. The company, currently valued at $300.48M, closed the last trade at $5.53 per share which meant it lost -$0.09 on the day or -1.60% during that session. The EBS stock price is -173.06% off its 52-week high price of $15.10 and 67.09% above the 52-week low of $1.82.
The consensus among analysts is that Emergent Biosolutions Inc (EBS) is Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 2 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Sporting -1.60% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the EBS stock price touched $5.53 or saw a rise of 14.92%. Year-to-date, Emergent Biosolutions Inc shares have moved -42.15%, while the 5-day performance has seen it change -13.46%. Over the past 30 days, the shares of Emergent Biosolutions Inc (NYSE:EBS) have changed -44.70%.
Wall Street analysts have a consensus price target for the stock at $51.5, which means that the shares’ value could jump 89.26% from current levels. The projected low price target is $38.0 while the price target rests at a high of $65.0. In that case, then, we find that the current price level is -1075.41% off the targeted high while a plunge would see the stock gain -587.16% from current levels.
Emergent Biosolutions Inc (EBS) estimates and forecasts
The company’s shares have lost -26.46% over the past 6 months.
EBS Dividends
Emergent Biosolutions Inc is expected to release its next earnings report in April this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
The top two institutional holders are BLACKROCK INC. with over 3.84 million shares worth more than $26.18 million. As of 2024-06-30, BLACKROCK INC. held 7.3551% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 3.67 million shares as of 2024-06-30. The firm’s total holdings are worth over $25.0 million and represent 7.0234% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Avantis U.S. Small Cap Value ETF and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF . As of Nov 30, 2024 , the former fund manager holds about 3.09% shares in the company for having 1.68 shares of worth $9.28 million while later fund manager owns 1.65 shares of worth $9.12 million as of Dec 31, 2024 , which makes it owner of about 3.03% of company’s outstanding stock.
